This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV-negative relapsed PBL can be treated successfully and consolidated with an allogeneic haploidentical hematopoietic cell transplantation.
Keywords: daratumumab; haploidentical transplantation; novel therapies; plasmablastic lymphoma; relapse.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.